Search

Your search keyword '"Anderson, Annaliesa S"' showing total 161 results

Search Constraints

Start Over You searched for: Author "Anderson, Annaliesa S" Remove constraint Author: "Anderson, Annaliesa S" Database Unpaywall Remove constraint Database: Unpaywall
161 results on '"Anderson, Annaliesa S"'

Search Results

1. Contributors

3. Structure-Based Design of a Highly Immunogenic, Conformationally Stabilized FimH Antigen for a Urinary Tract Infection Vaccine

4. Development of a sequence-based in silico OspA typing method for Borrelia burgdorferi sensu lato

5. Development and validation of a 6-plex Luminex-based assay for measuring human serum antibodies to group B streptococcus capsular polysaccharides

6. Interlaboratory comparison of a multiplex immunoassay that measures human serum IgG antibodies against six-group B streptococcus polysaccharides

7. Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18–49 years of age: Results of a randomized phase 3 study

8. Association between anti-capsular IgG levels at birth and risk of invasive group B streptococcus disease in Finnish newborns: a retrospective case–control study

9. Correction: Neutrophil killing of Staphylococcus aureus in diabetes, obesity and metabolic syndrome: a prospective cellular surveillance study

10. Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial

11. Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial

13. A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age

14. A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds

15. 385. Safety and Immunogenicity of a Variant-adapted Bivalent (Original/Omicron BA.4/BA.5) BNT162b2 COVID-19 Vaccine Given as a Booster (Dose 4) to 5- to 11-Year-Old Children Who Previously Received 3 Doses of Original BNT162b2

16. 1941. Coadministration of Bivalent Respiratory Syncytial Virus (RSVpreF) Vaccine With Influenza Vaccine in Older Adults

17. 1632. Bivalent RSV Prefusion F-Based Subunit Vaccine Generates High Neutralizing Titers in Older Adults

18. 362. Safety and Immunogenicity of a Variant-adapted Bivalent (Original/Omicron BA.4/BA.5) BNT162b2 COVID-19 Vaccine Given as a Booster (Dose 4) to Toddlers and Children 6 Months to < 5 Years of Age Who Previously Received Original BNT162b2 as a 3-Dose Primary Series

20. 1634. Respiratory Syncytial Virus-Associated Health Care Utilization in the Pivotal Phase 3 Trial RSV Vaccine Efficacy Study In Older Adults Immunized Against RSV Disease (RENOIR)

21. 1630. Clinical Profile of Acute Respiratory Illness (ARI) Events in the Phase 3 Trial The RSV Vaccine Efficacy Study iN Older Adults Immunized against RSV Disease (RENOIR)

25. A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 Years

26. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial

27. Potential for Maternally Administered Vaccine for Infant Group B Streptococcus

28. Calibration of a serum reference standard for Group B streptococcal polysaccharide conjugate vaccine development using surface plasmon resonance

29. Therapeutics for COVID-19

30. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults

31. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants

32. Identification of a Novel Keto Sugar Component in Streptococcus pneumoniae Serotype 12F Capsular Polysaccharide and Impact on Vaccine Immunogenicity

33. Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine

34. Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1–9 years: two phase 2 randomised, controlled, observer-blinded studies

35. Human Infection Challenge with Serotype 3 Pneumococcus

36. 2134. A Phase 2 Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Booster Dose of a Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine (GBS6)

37. LB748. Efficacy And Safety Of Bivalent Respiratory Syncytial Virus (RSVpreF) Vaccine In Older Adults

38. Generation of a VeroE6 Pgp gene knock out cell line and its use in SARS-CoV-2 antiviral study

41. Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine

43. Semisynthetic Glycoconjugate Vaccine Candidates against Escherichia coli O25B Induce Functional IgG Antibodies in Mice

45. Streptococcus pneumoniae serotype 15B polysaccharide conjugate elicits a cross-functional immune response against serotype 15C but not 15A

47. Protocol for a phase IV double-blind randomised controlled trial to investigate the effect of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine on pneumococcal colonisation using the experimental human pneumococcal challenge model in healthy adults (PREVENTING PNEUMO 2)

48. Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir

50. Preclinical Immunogenicity and Efficacy of Optimized O25b O-Antigen Glycoconjugates To Prevent MDR ST131 E. coli Infections

Catalog

Books, media, physical & digital resources